Valuation Doesn't Equal Share Price (and That Goes Double for Biotech)
Most investors realize that share price is meaningless when comparing companies. A company at $50 per share might actually be worth more than a company at $100 per share because a company's value is determined by the number of outstanding shares in addition to the share price.
But in biotech, you can't even compare the current price of a company's shares to the price a year (or less) ago. MannKind , for instance, ran up the day after its positive advisory committee meeting. While it didn't reach its 52-week high, investors are actually valuing the company more than it was at its previous high because MannKind has sold shares in the interim.
In the following video, Fool contributor Brian Orelli and health-care bureau chief Max Macaluso talk about why looking at a company's market cap is more important than its share price and discuss a few other examples -- Galena Biopharma , Sangamo BioSciences , and ANI Pharmaceuticals -- of companies with market caps that have grown much larger than their stock price because they've sold shares.
Too basic? Get an advanced degree from Warren Buffett
Warren Buffett has made billions through his investing and he wants you to be able to invest like him. Through the years, Buffett has offered up investing tips to shareholders of Berkshire Hathaway. Now you can tap into the best of Warren Buffett's wisdom in a new special report from The Motley Fool. Click here now for a free copy of this invaluable report.
The article Valuation Doesn't Equal Share Price (and That Goes Double for Biotech) originally appeared on Fool.com.Brian Orelli, Max Macaluso, and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.